文献速递妇产影像儿科影像心血管US

母亲肥胖对胎儿心脏筛查的影响:哪种随访策略具有成本效益

Impact of maternal obesity on fetal cardiac screening: which follow-up strategy is cost-effective?
PubMed 文献 · Ultrasound Obstet Gynecol · 2020-01-01

该成本效益分析构建非肥胖、肥胖和III级肥胖三个决策模型,比较五种胎儿心脏筛查不完整后的随访策略。结果显示,不做随访超声直接转诊胎儿超声心动图检出更多先心病但超过10万美元/QALY阈值;一次随访超声且不做胎儿超声心动图为所有体重指数组最具成本效益的策略。

要点

  • 胎儿心脏筛查不完整时,一次随访超声且不转诊胎儿超声心动图为最具成本效益策略。
  • 不做随访超声直接转诊胎儿超声心动图可多检出先心病,但超过成本效益阈值。
  • 两次随访超声联合或不联合胎儿超声心动图均为劣势策略(成本更高且效果更差)。

核心结论

  • 对于胎儿心脏筛查不完整的非肥胖和肥胖孕妇,最佳先心病随访筛查策略为不再超声随访而立即转诊胎儿超声心动图,但该策略不具成本效益。
  • 考虑成本时,一次随访超声且不做胎儿超声心动图为优先策略。
  • 蒙特卡洛模拟显示,非肥胖和肥胖孕妇中一次随访超声且不做胎儿超声心动图为最优策略的比例分别为97%、93%和86%。
  • 作者认为,初次心脏筛查不完整的非肥胖和肥胖孕妇均应接受一次随访超声。

研究设计与样本

  • 成本效益分析,构建非肥胖、肥胖和III级肥胖三个决策分析模型,比较五种随访策略。
  • 理论队列为美国4000000例次出生,模型旨在识别重大先心病胎儿。
  • 评估结局包括新生儿死亡和神经发育障碍,支付意愿阈值为每质量调整生命年100000美元。
  • 进行基础案例、敏感性分析和蒙特卡洛模拟。

诊断标准与关键数值

  • 与非肥胖、肥胖和III级肥胖女性基线策略(一次随访超声且不做胎儿超声心动图)相比,不做随访超声直接转诊胎儿超声心动图分别多检出7%、25%和82%的先心病胎儿。
  • 不做随访超声直接转诊胎儿超声心动图超过每质量调整生命年100000美元阈值,因此不具成本效益。
  • 所有体重指数组中,一次随访超声且不做胎儿超声心动图为具成本效益策略。
  • 两次随访超声不做胎儿超声心动图和两次随访超声联合胎儿超声心动图均为劣势策略(成本更高且效果更差),一次随访超声联合胎儿超声心动图超过成本效益阈值。
  • 蒙特卡洛模拟中,一次随访超声且不做胎儿超声心动图在非肥胖、肥胖和III级肥胖模型分别于97%、93%和86%的试验中为最优策略。

临床应用与阅片要点

  • 作者结论认为,初次心脏筛查不完整的非肥胖和肥胖孕妇均应接受一次随访超声。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To perform a cost-effectiveness analysis of different follow-up strategies for non-obese and obese women who had incomplete fetal cardiac screening for major congenital heart disease (CHD).

METHODS: Three decision-analytic models, one each for non-obese, obese and Class-III-obese women, were developed to compare five follow-up strategies for initial suboptimal fetal cardiac screening. The five strategies were: (1) no follow-up ultrasound (US) examination but direct referral to fetal echocardiography (FE); (2) one follow-up US, then FE if fetal cardiac views were still suboptimal; (3) up to two follow-up US, then FE if fetal cardiac views were still suboptimal; (4) one follow-up US and no FE; and (5) up to two follow-up US and no FE. The models were designed to identify fetuses with major CHD in a theoretical cohort of 4 000 000 births in the USA. Outcomes related to neonatal mortality and neurodevelopmental disability were evaluated. A cost-effectiveness willingness-to-pay threshold was set at US$100 000 per quality-adjusted life year (QALY). Base-case and sensitivity analysis and Monte-Carlo simulation were performed.

RESULTS: In our base-case models for all body mass index (BMI) groups, no follow-up US, but direct referral to FE led to the best outcomes, detecting 7%, 25% and 82% more fetuses with CHD in non-obese, obese and Class-III-obese women, respectively, compared with the baseline strategy of one follow-up US and no FE. However, no follow-up US, but direct referral to FE was above the US$100 000/QALY threshold and therefore not cost-effective. The cost-effective strategy for all BMI groups was one follow-up US and no FE. Both up to two follow-up US with no FE and up to two follow-up US with FE were dominated (being more costly and less effective), while one follow-up US with FE was over the cost-effectiveness threshold. One follow-up US and no FE was the optimal strategy in 97%, 93% and 86% of trials in Monte-Carlo simulation for non-obese, obese and Class-III-obese models, respectively.

CONCLUSION: For both non-obese and obese women with incomplete fetal cardiac screening, the optimal CHD follow-up screening strategy is no further US and immediate referral to FE; however, this strategy is not cost-effective. Considering costs, one follow-up US and no FE is the preferred strategy. For both obese and non-obese women, Monte-Carlo simulations showed clearly that one follow-up US and no FE was the optimal strategy. Both non-obese and obese women with initial incomplete cardiac screening examination should therefore be offered one follow-up US. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Bak GS, Shaffer BL, Madriago E, et al. Impact of maternal obesity on fetal cardiac screening: which follow-up strategy is cost-effective? Ultrasound Obstet Gynecol. 2020. PMID: 31614030. doi:10.1002/uog.21895

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。